Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions: Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Thymic Humoral Factor, Zidovudine; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Kidney Transplantation
Interventions: Tacrolimus + Ketoconazole, Then Tacrolimus alone, Tacrolimus alone, Then Tacrolimus + Ketoconazole; Drug
Lead sponsor: Sony Tuteja; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Smoking, Smoking Cessation, HIV
Interventions: Nicoderm C-Q Transdermal Product, Adherence to Antiretroviral Therapy Counseling, Behavioral Smoking Cessation Counseling, "Crave-to-Quit" app, vDOT "emocha" app; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise, Dietary Supplement
Interventions: Phaeosol group, Placebo group; Dietary Supplement
Lead sponsor: Microphyt; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Aspirin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more

Conditions: Maternal Opioid Use Disorder, Opioid Exposed Infant
Interventions: fetal monitoring, Buprenorphine Naloxone; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: OMP-54F28, Nab-Paclitaxel and Gemcitabine; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more

Conditions: Endometrial Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 55
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 32 more

Conditions: Heart Failure
Interventions: Zepatier; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: PTSD - Post Traumatic Stress Disorder, Insomnia, TBI (Traumatic Brain Injury)
Interventions: Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC); Drug · Behavioral
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Non-Small Cell Carcinoma, Pleural Disorder
Interventions: Porfimer Sodium, Video-Assisted Thoracic Surgery, Photodynamic Therapy, Intraoperative PDT; Drug · Procedure · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions: Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 26
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 21 more

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hodgkin Lymphoma
Interventions: brentuximab vedotin, nivolumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Duarte, California • Stanford, California • Boston, Massachusetts + 10 more

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
Interventions: Decitabine, Tagraxofusp-erzs; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 29
States / cities: Los Angeles, California • Menlo Park, California • San Jose, California + 19 more

Conditions: Seasonal Allergic Conjunctivitis
Interventions: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more

Conditions: Healthy Volunteers
Interventions: SPD422, Omeprazole; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Spinal Cord Injuries
Interventions: Brain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients

Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Maternal Buprenorphine-naloxone Treatment and the Infant

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Abemaciclib and Letrozole to Treat Endometrial Cancer

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

Suvorexant 3 - PE-PC

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI)